Aristea Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases, today announced that James Mackay, Ph.D., President and CEO, will participate in the following investor conferences in September and October:

UBS Private Company ConferenceDate: September 22, 2021  Time: 10:30 a.m. PTPresentation

Cantor Fitzgerald Healthcare ConferenceDate: September 29, 2021Time: 1 p.m. PTFireside Chat

Needham Biotech Private Company 1x1 ForumDate: October 19-20, 20211:1 Meetings

Archived versions of the virtual presentations/fire-side chats will be available through the Aristea website at www.aristeatx.com following the conferences.

About Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage immunology focused drug development company developing novel therapies to treat rare serious inflammatory diseases. The Aristea team is leveraging its broad industry expertise and proven success in drug development to form synergistic partnerships and build a pipeline of novel drugs. Aristea's lead program, RIST4721, is currently in Phase 2b clinical development. Aristea is headquartered in San Diego, CA.

To learn more, please visit www.aristeatx.com and follow us on social media @Aristeatx

For media inquiries contact:David Schull or Ignacio Guerrero-Ros, Ph.D.Russo Partners858-717-2310646-942-5604[email protected] [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/aristea-therapeutics-to-present-at-upcoming-investor-conferences-301379540.html

SOURCE Aristea Therapeutics